Recent Regulatory Updates Impacting the INSS and Pharmaceutical Industry

Recent Regulatory Updates Impacting the INSS and Pharmaceutical Industry

Introduction:

In recent times, there have been significant regulatory changes that have had a direct impact on both the INSS (National Institute of Social Security) and the pharmaceutical industry in Brazil. These changes, encompassed in the INSTRUÇÃO NORMATIVA PRES/INSS Nº 128, DE 28 DE MARÇO DE 2022, and the RESOLUÇÃO-RE Nº 2.374, DE 29 DE JUNHO DE 2023, bring forth new guidelines and revoked previous acts, shaping the landscape for both sectors. In this article, we will explore the key points of these regulatory updates and their implications for the INSS and the pharmaceutical industry.

Revocation of IN 77/2015:

One of the significant changes introduced by the INSTRUÇÃO NORMATIVA PRES/INSS Nº 128, DE 28 DE MARÇO DE 2022 is the revocation of the Instrução Normativa nº 77/PRES/INSS, issued on January 21, 2015. This revocation, as stated in Art. 672 of the INSTRUÇÃO NORMATIVA PRES/INSS Nº 128, marks a shift in the regulatory framework governing the INSS. The revocation of IN 77/2015 implies that the guidelines and provisions outlined in that instruction are no longer applicable.

Deferment of Petitions Related to Gerência-Geral de Medicamentos:

The RESOLUÇÃO-RE Nº 2.374, DE 29 DE JUNHO DE 2023, on the other hand, defers petitions related to the Gerência-Geral de Medicamentos (General Management of Medicines). This resolution, published in the Diário Oficial da União on July 3, 2023, grants approval for specific requests concerning the management of medications, specifically the cloridrato de atomoxetina ATENTAH 25351.013978/2021-15. This deferment holds significant implications for the pharmaceutical industry as it streamlines the process of approving specific medications, ensuring their availability to the public.

Common Points and Natural Connection:

Though seemingly unrelated, the revocation of IN 77/2015 by the INSTRUÇÃO NORMATIVA PRES/INSS Nº 128, DE 28 DE MARÇO DE 2022, and the deferment of petitions related to the Gerência-Geral de Medicamentos in the RESOLUÇÃO-RE Nº 2.374, DE 29 DE JUNHO DE 2023, share a common thread - the need for regulatory updates to adapt to evolving circumstances. Both these changes reflect the authorities' efforts to align regulations with current realities and streamline processes to better serve the public and industry stakeholders.

Insights and Unique Ideas:

The revocation of IN 77/2015 indicates that the INSS is actively reevaluating its operational guidelines. This move could signify a broader effort to modernize and simplify administrative processes within the organization. By revoking outdated instructions, the INSS aims to remove any unnecessary bureaucratic hurdles and ensure a more efficient and effective service delivery to its beneficiaries.

Furthermore, the deferment of petitions related to the Gerência-Geral de Medicamentos demonstrates the authorities' commitment to expediting the approval of critical medications. This resolution enables the prompt availability of cloridrato de atomoxetina ATENTAH 25351.013978/2021-15 and other essential drugs, addressing the needs of patients and healthcare providers alike. The proactive approach taken by the regulatory bodies showcases a willingness to adapt to the evolving demands of the pharmaceutical industry.

Actionable Advice:

1. Stay Updated: In light of these regulatory changes, it is crucial for stakeholders in both the INSS and the pharmaceutical industry to stay informed about updates and amendments. Regularly checking official publications, such as the Diário Oficial da União, will ensure that you are aware of any new guidelines or revocations that may impact your operations.

2. Streamline Processes: With the revocation of outdated instructions, the INSS is signaling a move towards more streamlined and efficient processes. Take this opportunity to evaluate your own organizational procedures and identify areas where simplification and automation can be implemented. Streamlining processes not only enhances productivity but also improves the overall experience for clients and customers.

3. Seek Regulatory Guidance: If you are a pharmaceutical industry professional seeking approval for specific medications, it is advisable to seek regulatory guidance from the Gerência-Geral de Medicamentos. Engaging with the regulatory authorities will help you navigate the approval process effectively and ensure compliance with the latest regulations.

Conclusion:

The revocation of IN 77/2015 by the INSTRUÇÃO NORMATIVA PRES/INSS Nº 128, DE 28 DE MARÇO DE 2022, and the deferment of petitions related to the Gerência-Geral de Medicamentos in the RESOLUÇÃO-RE Nº 2.374, DE 29 DE JUNHO DE 2023, represent significant regulatory changes impacting the INSS and the pharmaceutical industry in Brazil. These changes reflect the authorities' dedication to adapt regulations to current circumstances and streamline processes for improved service delivery. By staying updated, streamlining processes, and seeking regulatory guidance, stakeholders can navigate these changes effectively and ensure compliance with the latest guidelines.